Compare BEEM & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BEEM | ATNM |
|---|---|---|
| Founded | 2006 | 2000 |
| Country | United States | United States |
| Employees | 220 | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 31.7M |
| IPO Year | N/A | 2013 |
| Metric | BEEM | ATNM |
|---|---|---|
| Price | $1.15 | $0.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $3.50 | ★ $4.50 |
| AVG Volume (30 Days) | ★ 395.2K | 99.6K |
| Earning Date | 04-09-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.17 |
| EPS | N/A | ★ 0.71 |
| Revenue | N/A | ★ $90,000.00 |
| Revenue This Year | $40.48 | N/A |
| Revenue Next Year | $32.17 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 11.11 |
| 52 Week Low | $0.97 | $0.74 |
| 52 Week High | $4.04 | $1.81 |
| Indicator | BEEM | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 33.74 |
| Support Level | $1.13 | N/A |
| Resistance Level | $1.66 | $1.38 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 88.08 | 24.44 |
Beam Global is a clean-technology innovation company. It develop, design, engineer, manufacture, and sell high-quality, renewably energized infrastructure products for electric vehicle ( EV ) charging, infrastructure for Smart Cities (the interconnected physical and digital elements within a city that utilize technology to enhance efficiency, sustainability, and quality of life for residents), energy security and disaster preparedness and energy-dense battery solutions in safe, compact and form-factors. Additionally, the company manufactures structures with electronic integration such as streetlighting, cell towers and energy infrastructure products as well as power electronics including invertors, charge controllers, power supplies and LED lighting.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of targeted radiotherapies using its Antibody Radiation Conjugates (ARCs) platform, which combines monoclonal antibodies with radioisotopes to selectively target and destroy cancer cells. The company's product candidates include Iomab-B, an iodine-131 based radiotherapy for conditioning prior to hematopoietic stem cell transplantation, and Actimab-A, an actinium-225 based radiotherapy in clinical development for acute myeloid leukemia. The company is also advancing additional programs, including Iomab-ACT for cell and gene therapy conditioning and other preclinical candidates targeting solid tumors.